Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 11/2024

Inhalt (26 Artikel)

Increasing monocytes after lung cancer surgery triggers the outgrowth of distant metastases, causing recurrence

  • Open Access
  • Research

Yo Kawaguchi, Keigo Okamoto, Yoko Kataoka, Kohei Shibata, Hiroki Saito, Takuya Shiratori, Keiko Ueda, Yasuhiko Ohshio, Jun Hanaoka

High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma

  • Open Access
  • Brief Report

Samuel L. Hill, Gessa Sugiyarto, Jack Harrington, Edward James, Timothy J. Underwood, Tim Elliott

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

  • Open Access
  • Research

Daiki Murata, Koichi Azuma, Kenta Murotani, Akihiko Kawahara, Yuuya Nishii, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino

Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers

  • Open Access
  • Research

Jung Ho Kim, Jiyun Hong, Ji Ae Lee, Minsun Jung, Eunwoo Choi, Nam-Yun Cho, Gyeong Hoon Kang, Sangwoo Kim

The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China

  • Open Access
  • Research

Hao Cui, Yongpu Yang, Liqiang Song, Zhen Yuan, Linde Sun, Jiajun Du, Yuyuan Lu, Ning Ning, Jianxin Cui, Yan Shi, Lin Chen, Bo Wei

Immunogenomic features of radiologically distinctive nodules in multiple primary lung cancer

  • Open Access
  • Research

Mei-Cheng Chen, Hao-Shuai Yang, Zhi Dong, Lu-Jie Li, Xiang-Min Li, Hong-He Luo, Qiong Li, Ying Zhu

Stat3-mediated Atg7 expression regulates anti-tumor immunity in mouse melanoma

  • Open Access
  • Brief Report

Sarah M. Zimmerman, Erin Suh, Sofia R. Smith, George P. Souroullas

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

  • Open Access
  • Research

Jin Li, Yuxian Bai, Zhendong Chen, Jieer Ying, Yabing Guo, Weijia Fang, Feng Zhang, Jianping Xiong, Tao Zhang, Zhiqiang Meng, Jingdong Zhang, Zhenggang Ren, Chunyi Hao, Yajin Chen, Xiaoyan Lin, Hongming Pan, Fuxiang Zhou, Xin Li, Fan Yu, Juan Zhang, Zhang Zhang, Shukui Qin

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

  • Open Access
  • Research

Yunxin Lu, Yin Jin, Furong Liu, Zixian Wang, Wen Zhou, Yang Zhang, Bing Bai, Yun Wang, Zhiqiang Wang, Man Nie, Huiyan Luo, Xiaoli Wei, Chuqiao Liang, Guifang Guo, Miaozhen Qiu, Jianwen Chen, Yu Liu, Shengping Li, Yuhong Li, Fenghua Wang, Feng Wang, Peidong Chi, Dongsheng Zhang

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma

  • Open Access
  • Research

Colin H. Quinn, Janet R. Julson, Hooper R. Markert, Nazia Nazam, Swatika Butey, Jerry E. Stewart, Jennifer C. Coleman, James M. Markert, Jianmei W. Leavenworth, Elizabeth A. Beierle

Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence

  • Open Access
  • Research

Danyang Zhou, Mei Li, Wei Wu, Ying Wu, Qiaohong Nong, Shusen Wang, Ruoxi Hong

Correction to: Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells

  • Open Access
  • Correction

Ibrahim El-Seraf, Isabella Micallef Nilsson, Alina Moter, Zhe Duan, Jonas Mattsson, Isabelle Magalhaes

Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy

  • Open Access
  • Research

Zihang Mai, Kongjia Luo, Xinye Wang, Xiuying Xie, Lanlan Pang, Hong Yang, Jing Wen, Jianhua Fu

Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents

  • Open Access
  • Research

Dingyi Yang, Erha Munai, Siwei Zeng, Dan Tao, Ze Yuan, Liang Du, Wei Zhou, Yongzhong Wu, Xiao-Dong Zhu

Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma

  • Open Access
  • Research

Shih-Hung Yang, Sung-Hsin Kuo, Jen-Chieh Lee, Bang-Bin Chen, Yan-Shen Shan, Yu-Wen Tien, Sz-Chi Chiu, Ann-Lii Cheng, Kun-Huei Yeh

Disruptions in antigen processing and presentation machinery on sarcoma

  • Open Access
  • Research

Salvatore Lorenzo Renne, Laura Sama’, Sonia Kumar, Omer Mintemur, Laura Ruspi, Ilaria Santori, Federico Sicoli, Alexia Bertuzzi, Alice Laffi, Arturo Bonometti, Piergiuseppe Colombo, Vittoria D’amato, Alessandra Bressan, Marta Scorsetti, Luigi Terracciano, Pierina Navarria, Maurizio D’incalci, Vittorio Quagliuolo, Fabio Pasqualini, Fabio Grizzi, Ferdinando Carlo Maria Cananzi

Secretome and immune cell attraction analysis of head and neck cancers

  • Open Access
  • Research

Tara Muijlwijk, Niels E. Wondergem, Fatima Ekhlas, Naomi Remkes, Dennis N. L. M. Nijenhuis, Lennart Fritz, Sonja H. Ganzevles, Iris H. C. Miedema, C. René Leemans, Jos B. Poell, Ruud H. Brakenhoff, Rieneke van de Ven

Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study

  • Open Access
  • Research

Jhe-Cyuan Guo, Ta-Chen Huang, Hung-Yang Kuo, Chia-Chi Lin, Feng-Ming Hsu, Jason Chia-Hsien Cheng, Yen-Lin Huang, Min-Shu Hsieh, Pei-Ming Huang, Jang-Ming Lee, Shu-Ling Wu, Chih-Hung Hsu

A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts

  • Open Access
  • Research

Keunpyo Lim, San Ha Han, Sein Han, Ji Yoon Lee, Hong Seo Choi, Dongho Choi, Chun Jeih Ryu

Recent clinical researches and technological development in TIL therapy

  • Open Access
  • Review

Satoko Matsueda, Lei Chen, Hongmei Li, Hui Yao, Fuli Yu

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors

  • Open Access
  • Review

Jyoti Malhotra, Subhajyoti De, Kim Nguyen, Percy Lee, Victoria Villaflor

Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis

  • Open Access
  • Research

Ruxuan Chen, Yujie Shi, Nan Fang, Chi Shao, Hui Huang, Ruili Pan, Yan Xu, Mengqi Wang, Xiangning Liu, Kai Xu, Rui Zhu, Mengzhao Wang

Correction to: Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK‑mediated upregulation of PD‑L1

  • Open Access
  • Correction

Ruizhi Zhang, Gan Mao, Yu Tang, Chong Li, Yisong Gao, Wenxiang Nie, Tianyu Song, Suao Liu, Peng Zhang, Kaixiong Tao, Wei Li

Neu im Fachgebiet Onkologie

Dänische Zwillingsstudie deutet auf erhöhtes Krebsrisiko bei Tätowierten hin

Haben Tattoo-Träger und -Trägerinnen ein erhöhtes Risiko, an Hautkrebs oder einem Lymphom zu erkranken? Die Ergebnisse einer Zwillingsstudie aus Dänemark scheinen dafür zu sprechen. Die Forschungsgruppe rät vorerst zur Zurückhaltung beim Tätowieren.

Weniger PSA-Screening, mehr fortgeschrittene Tumoren

Eine Empfehlung gegen das Prostatakrebs-Screening, die mehrere Jahre in den Leitlinien des Royal Australasian College of General Practitioners gegeben wurde, hat sich nicht nur auf die Rate von PSA-Tests negativ ausgewirkt.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

Muss man wirklich auch die letzte Krebszelle eliminieren?

Genauere Prognoseabschätzung, bessere Therapiesteuerung und eine schnellere Entwicklung innovativer Behandlungsansätze – der Messung der minimalen Resterkrankung (MRD) wird ein enormes Potenzial attestiert. Eine Übersichtsarbeit unterstreicht jetzt aber: Es gibt noch blinde Flecken.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.